Advertisement

Topics

Latest "Biogen Incorporated" News Stories

23:07 EST 13th December 2017 | BioPortfolio

Here are the most relevant search results for "Biogen Incorporated" found in our extensive news archives from over 250 global news sources.

More Information about Biogen Incorporated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biogen Incorporated for you to read. Along with our medical data and news we also list Biogen Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biogen Incorporated Companies for you to search.

Showing "Biogen Incorporated" News Articles 1–25 of 496

Monday 11th December 2017

Alzheimer's Disease [2017] [Report Updated: 01102017] Prices from USD $8145

Do KOLs see a future for betaamyloid as a target in Alzheimer's? Despite the inexorable attrition rate, both big pharma and small biotechs continue to invest in Alzheimer's disease RD. Is the amyloid hypothesis dead or could the right drug candidate, studied in an optimally designed trial, gain approval for this much sought after indication? KOLs weigh in on how trials could be optimised and what ...


Saturday 9th December 2017

Global Biopharma Market Research Report 20112023 [Report Updated: 09112017] Prices from USD $3610

SummaryThe global Biopharma market will reach xxx Million USD in 2017 with CAGR xx% 20182023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes major produ...

Global Biopharma Market Data Survey Report 2025 [Report Updated: 07112017] Prices from USD $1500

SummaryThe global Biopharma market will reach Volume Million USD in 2017 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Average market price by SUKMajor applicationsKey manufacturers are included based o...


Thursday 7th December 2017

Spark's Hemophilia B Gene Therapy SPK9001 Packs A Punch And Saves Big Bucks

A New England Journal of Medicine publication and editorial highlighted a small study of ten patients in which one infusion...    

Biogen to Present at the Guggenheim 5th Annual Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Guggenheim 5th Annual Healthcare Conference. The webcast will be live on Wednesday, December 13, 2017 at 12:00 p.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be avail

Novartis' Kisqali Impresses In Premenopausal Breast Cancer As Market Crowds

Updated data from the MONALEESA-7 study shows the extent of its progression-free survival benefit in premenopausal women with advanced breast...   

Appointments: EMD Serono, Cellectis, Shire, Bayer, Biogen, Horizon, Alligator, Faron, Ironwood, Vectura

The latest biopharma industry appointments include R&D leadership appointments at Shire, Bayer, Alligator and Horizon Pharma, new chief medical officers...   

Novartis tender offer for Advanced Accelerator Applications commences

Novartis International AG / Novartis tender offer for Advanced Accelerator Applications commences . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Basel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S...

Wednesday 6th December 2017

Biogen inks outcomes-based contract for MS meds

A deal with Prime Therapeutics will link the cost of several of the biotech's multiple sclerosis drugs to patient adherence and clinical value. 

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Financing led by GV to focus on lead programs for next-generation oncology cell therapies Proprietary platform enables installation of pharmacologic operating systems in cell and gene therapy products to provide treating physicians with precise and dynamic control of engineered cells in patients Obsidian Therapeutics, Inc., a biotechnology com...

Tuesday 5th December 2017

Acorda sells Fampyra royalties to HealthCare Royalty Partners for $40mm

HealthCare Royalty Partners (HCRP) is providing Acorda Therapeutics Inc. with $40mm in exchange for royalty revenues (up to a...

Biogen appoints Jeff Capello as executive VP and CFO

He will lead the company's business and finance planning functions

Monday 4th December 2017

Management Tracks: Athenex, Biogen

Takeda exec jumps ship to join Biogen

US biotech major Biogen has appointed Mark Hernon as senior vice president, chief information officer,…

Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink

CALGARY, Alberta, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed its previously announced private placement of 60,416,667 equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. ("Hepalink") at a price of $1.44 per unit for gross proceeds of $87 million. Each unit was comprised ...

Biogen Appoints Mark Hernon as SVP, Chief Information Officer

Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4. In his new role, Mr. Hernon will lead the global information technology (IT) organization and be responsible for accelerating and supporting Biogen’s operations through delivery of innovative technology ...

Sunday 3rd December 2017

Biogen Continues Bulking Up Its C-Suite With Appointment of Ex-Takeda Exec as CIO

Mr. Hernon joins Biogen with more than 30 years of experience in IT and strategic leadership. In recent years with Takeda Pharmaceuticals.

Vernalis Plc VER Financial and Strategic SWOT Analysis Review [Report Updated: 25102017] Prices from USD $125

Vernalis Plc VER Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your busi...

Friday 1st December 2017

These Indications Support Higher Biogen Stock Prices

BIIB Stock Is Primed for Higher Prices The markets are absolutely on fire and the indices are consistently forging new highs. The biotechnology sector has been lagging behind the major market indic...

Biogen agrees to outcomes-based contract for MS portfolio

Copley Scientific to showcase new TPK™ 2100 Critical Flow Controller for dry powder inhaler testing at DDL2017

A highly automated system to speed up testing, improve reproducibility, and enhance data output and recording Monday 27th November: Nottingham, UK: Copley Scientific, the world’s leading manufacturer of inhaler test equipment, will be presenting its new 3rd generation Critical Flow Controller – the TPK™ 2100 – for the testing of dry powder inhalers (DPIs) at the 2017 Dr...

Copley Scientific introduces new, upgraded breath simulators for inhaled product testing.

13th November 2017: Nottingham, UK: Copley Scientific, the world’s leading manufacturer of inhaler test equipment, launches new advanced breath simulators, the BRS 2100 and BRS 3100, for orally inhaled product (OIP) development and testing. In recent years, in response to regulatory and pharmacopoeial changes, and the drive to ensure closer correlation between in vivo and in vitro performa...

EC approval for trastuzumab biosimilar Ontruzant

South Korean electronics giant Samsung and biotechnology company Biogen Idec’s joint venture Samsung Bioepis announced on 20 November 2017 that it had received European Commission (EC) approval for its biosimilar trastuzumab product Ontruzant (SB3).

Thursday 30th November 2017

Global Biopharma Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1500

SummaryThe global Biopharma market will reach Volume Million USD in 2017 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Average market price by SUKMajor applicationsKey manufacturers are included based o...

U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients

U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients Cambridge, Ma.  - November 30, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the world's leading biotechnology company in rare diseases, today announced that the U.S. Food and Drug Administra...


Quick Search
Advertisement
 

News Quicklinks